Abstract 846P
Background
The widespread implementation of COVID-19 vaccines achieved a great success in the general population. However, an unmet medical need exists for onco-hematological and other immunocompromised patients for whom vaccines may not provide optimal protection. Identifying these patients to consider additional layers of protection, including passive immunization with monoclonal antibodies, has been a challenge. Herein, we propose an artificial Intelligence (AI) driven methodology to aid the identification of patients at risk of severe COVID-19 via a minimal number of variables.
Methods
A multi-centric training (340 patients) and an external testing (103 patients) retrospective cohort with homogeneous population characteristics were built. Inclusion referred to hematological or lung cancer patients with COVID-19 infection and absence – except vaccination – of any COVID-19 preventive treatments. The E-CRF included 70+ clinical and demographic variables. Patients were classified into two different COVID-19 severity populations, mild and moderate/severe, based on oxygen support. We sought to identify (i) the minimal set of independent variables (signatures) characterizing these populations, and (ii) the best AI solution acting on these signatures to predict the severity of infection via an end-to-end integration of statistical importance and AI methods.
Results
Using the training cohort we identified 7 variables (age and cancer stage ranked as most important) enabling the prediction of moderate/severe cases with a balanced accuracy of 72% (AUC 0,76) on the internal cohort. The model performed equally well on the external testing cohort yielding a similar balanced accuracy of 73% (AUC 0,77). Most importantly the model reached a 85% performance on the severe cases.
Conclusions
The conducted analysis leads to promising insights towards identifying onco-hematological patients who are most vulnerable to develop severe COVID-19. This may help to offer additional prevention strategies to protect them from COVID-19 and can potentially be further extended to other immunocompromised populations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
TheraPanacea, Paris.
Funding
AstraZeneca.
Disclosure
J-Y. Blay: Financial Interests, Institutional, Invited Speaker: MSD, PharmaMar; Financial Interests, Institutional, Advisory Board: Bayer, GSK, Roche; Financial Interests, Personal, Advisory Board: Deciphera; Financial Interests, Personal, Other, member of the supervisory board. No remunerations in 2021 and 2022.: Innate pharma; Financial Interests, Personal, Member of Board of Directors: Transgene; Financial Interests, Institutional, Funding: MSD, BMS, Deciphera; Financial Interests, Institutional, Research Grant: AstraZeneca, Roche, Bayer, GSK, Novartis, OSE pharma. P-E. Heudel: Financial Interests, Personal, Advisory Board: AstraZeneca, Pfizer, Novartis, Seagen, Lilly, MSD, Gilead; Financial Interests, Personal, Ownership Interest: GeodAIsics. C. Bigenwald: Financial Interests, Personal, Advisory Board: Janssen. L. Albiges: Financial Interests, Institutional, Other, Consulting: Astellas, BMS, Eisai, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche, Merck; Financial Interests, Personal, Other, Honoraria: Novartis; Non-Financial Interests, Principal Investigator, Clinical trial steering committee: Pfizer, BMS, AVEO, AstraZeneca, MSD; Non-Financial Interests, Principal Investigator: Ipsen; Non-Financial Interests, Other, Clinical trial steering committee: Roche, Exelixis; Non-Financial Interests, Member: ASCO; Non-Financial Interests, Other, Medical Steering Committee: Kidney Cancer Association; Non-Financial Interests, Other, Member of the Renal Cell Carcinoma Guidelines Panel: European Association of Urology (EAU). F. André: Financial Interests, Personal, Advisory Board: Lilly France; Financial Interests, Institutional, Advisory Board: AstraZeneca, Daiichi Sankyo, Roche, Lilly, Pfizer, Owkin, Novartis, Guardant Health; Financial Interests, Institutional, Advisory Board, I'm member of the advisory board of Relay Therapeutics. The compensation is going to Gustave Roussy: relay therapeutics; Financial Interests, Institutional, Research Grant: AstraZeneca, Lilly, Novartis, Pfizer, Roche, Daiichi Sankyo, Guardant Health, Owkin; Other, Founder: Pegacsy. All other authors have declared no conflicts of interest.
Resources from the same session
968P - High sensitivity routine blood based detection of HCC: An AI model from 220k patients
Presenter: Kin Nam Kwok
Session: Poster session 18
969P - Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data
Presenter: Ka Man Cheung
Session: Poster session 18
970P - Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Presenter: Choong-kun Lee
Session: Poster session 18
971P - Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China
Presenter: Zhongqi Fan
Session: Poster session 18
972P - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Presenter: Mara Persano
Session: Poster session 18
973P - Clinicopathologic and treatment outcome data in 165 fibrolamellar carcinoma patients
Presenter: Sunyoung Lee
Session: Poster session 18
974P - The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study from China
Presenter: Guoyue Lv
Session: Poster session 18
975P - The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Presenter: Kaoru Tsuchiya
Session: Poster session 18
976P - Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic radiation therapy or systemic therapy alone
Presenter: Alexander Piening
Session: Poster session 18